Key factors
symOCGN
exchUS
MCap259.06M
Beta3.68
EPS-0.32
Div date0000-00-00
Yesterday
symOCGN
exchUS
close1.78
50 Day MA0.678
200 Day MA0.512
52 Week High1.28
52 Week Low0.345
Target Price 6.33
Market Cap Mln259.06
Share statistics
Shares Outstanding256.50M
Shares Float252.37M
Percent Institutions10.34
PercentInsiders1.452
SharesShort24.36M
Short Ratio10.87
Shares Short Prior Month23.70M
Short Percent12.31
Revenue TTM -380.0
Gross Profit TTM -49.7M
EBITDA-80.3M
Diluted Eps TTM-0.32
earning
EPS Estimate Current Quarter -0.07
EPS Estimate Current Year -0.28
EPS Estimate Next Quarter -0.07
EPS Estimate Next Year -0.28
Earnings Share -0.32
Dividend
Dividend Date2019-09-30
Last Split Date 2019-09-30
Last Split Factor1:60
business
Enterprise Value Ebitda -2.63
Enterprise Value Revenue35591
Book Value /share 0.228
Price Book MRQ 4.436
Price Sales TTM 25069
ReturnOnAssetsTTM -0.53
ReturnOnEquityTTM-0.98
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic Sector Health Care
Gic Sub Industry Biotechnology
IndustryBiotechnology
SectorHealthcare
ISIN US67577C1053
CIK 1372299
Code OCGN
CUSIP 67577C105
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2024-03-08
Home Category Domestic
Fiscal Year End December
ForwardPE 15.22
Full Time Employees84.0
IPODate 2014-12-03
MostRecent Quarter2023-09-30
Contact
NameOcugen Inc
Address263 Great Valley Parkway, Malvern, PA, United States, 19355
Country NameUSA
Phone484 328 4701
Web URLhttps://www.ocugen.com
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.